Cecilia M. Shikuma to Antiretroviral Therapy, Highly Active
This is a "connection" page, showing publications Cecilia M. Shikuma has written about Antiretroviral Therapy, Highly Active.
Connection Strength
3.760
-
Ndhlovu LC, Umaki T, Chew GM, Chow DC, Agsalda M, Kallianpur KJ, Paul R, Zhang G, Ho E, Hanks N, Nakamoto B, Shiramizu BT, Shikuma CM. Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND). J Neurovirol. 2014 Dec; 20(6):571-82.
Score: 0.447
-
Shikuma CM, Ribaudo HJ, Zheng Y, Gulick RM, Meyer WA, Tashima KT, Bastow B, Kuritzkes DR, Glesby MJ. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. AIDS Res Hum Retroviruses. 2011 May; 27(5):461-8.
Score: 0.343
-
Nakamoto BK, McMurtray A, Davis J, Valcour V, Watters MR, Shiramizu B, Chow DC, Kallianpur K, Shikuma CM. Incident neuropathy in HIV-infected patients on HAART. AIDS Res Hum Retroviruses. 2010 Jul; 26(7):759-65.
Score: 0.334
-
Valcour V, Watters MR, Williams AE, Sacktor N, McMurtray A, Shikuma C. Aging exacerbates extrapyramidal motor signs in the era of highly active antiretroviral therapy. J Neurovirol. 2008 Oct; 14(5):362-7.
Score: 0.298
-
Shikuma CM, Valcour VG, Ratto-Kim S, Williams AE, Souza S, Gerschenson M, Day L, Kim JH, Shiramizu B. HIV-associated wasting in the era of highly active antiretroviral therapy: a syndrome of residual HIV infection in monocytes and macrophages? Clin Infect Dis. 2005 Jun 15; 40(12):1846-8.
Score: 0.234
-
Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, Evans S, Mulligan K. Changes in weight and lean body mass during highly active antiretroviral therapy. Clin Infect Dis. 2004 Oct 15; 39(8):1223-30.
Score: 0.224
-
Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A, Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clin Trials. 2003 Nov-Dec; 4(6):411-6.
Score: 0.210
-
Shikuma CM, Wojna V, De Gruttola V, Siriwardhana C, Souza SA, Rodriguez-Benitez RJ, Turner EH, Kallianpur K, Bolzenius J, Chow D, Matos M, Shiramizu B, Clements DM, Premeaux TA, Ndhlovu LC, Paul R. Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment. AIDS. 2023 11 01; 37(13):1987-1995.
Score: 0.206
-
Shikuma CM, Hu N, Milne C, Yost F, Waslien C, Shimizu S, Shiramizu B. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS. 2001 Sep 28; 15(14):1801-9.
Score: 0.182
-
Chow DC, Kagihara JM, Zhang G, Souza SA, Hodis HN, Li Y, Mitchell BI, Nakamoto BK, Kallianpur KJ, Keating SM, Norris PJ, Kohorn LB, Ndhlovu LC, Shikuma CM. Non-classical monocytes predict progression of carotid artery bifurcation intima-media thickness in HIV-infected individuals on stable antiretroviral therapy. HIV Clin Trials. 2016 05; 17(3):114-22.
Score: 0.124
-
Thao VP, Quang VM, Day JN, Chinh NT, Shikuma CM, Farrar J, Van Vinh Chau N, Thwaites GE, Dunstan SJ, Le T. High prevalence of PI resistance in patients failing second-line ART in Vietnam. J Antimicrob Chemother. 2016 Mar; 71(3):762-74.
Score: 0.122
-
Valcour VG, Ananworanich J, Agsalda M, Sailasuta N, Chalermchai T, Schuetz A, Shikuma C, Liang CY, Jirajariyavej S, Sithinamsuwan P, Tipsuk S, Clifford DB, Paul R, Fletcher JL, Marovich MA, Slike BM, DeGruttola V, Shiramizu B. HIV DNA reservoir increases risk for cognitive disorders in cART-na?ve patients. PLoS One. 2013; 8(7):e70164.
Score: 0.103
-
Phanuphak N, Ananworanich J, Teeratakulpisarn N, Jadwattanakul T, Kerr SJ, Chomchey N, Hongchookiat P, Mathajittiphun P, Pinyakorn S, Rungrojrat P, Praihirunyakit P, Gerschenson M, Phanuphak P, Valcour V, Kim JH, Shikuma C. A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine. Antivir Ther. 2012; 17(8):1521-31.
Score: 0.099
-
Le T, Farrar J, Shikuma C. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS. 2011 Mar 27; 25(6):871-2; author reply 872-3.
Score: 0.088
-
Chow DC, Stein JH, Seto TB, Mitchell C, Sriratanaviriyakul N, Grandinetti A, Gerschenson M, Shiramizu B, Souza S, Shikuma C. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. AIDS. 2010 Apr 24; 24(7):1019-23.
Score: 0.082
-
Valcour VG, Shiramizu BT, Shikuma CM. HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications. J Leukoc Biol. 2010 Apr; 87(4):621-6.
Score: 0.081
-
Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM. Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095). J Acquir Immune Defic Syndr. 2007 Apr 15; 44(5):540-50.
Score: 0.067
-
Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006 Aug 16; 296(7):769-81.
Score: 0.064
-
Shikuma CM, Day LJ, Gerschenson M. Insulin resistance in the HIV-infected population: the potential role of mitochondrial dysfunction. Curr Drug Targets Infect Disord. 2005 Sep; 5(3):255-62.
Score: 0.060
-
Chow DC, Richmond-Crum SM, Shimizu SM, Kohatsu J, Souza SA, Grandinetti A, Urada KK, Shikuma C. A descriptive epidemiologic study of HIV-infected individuals in Hawaii: report of the Hawaii Sero-Positivity and Medical Management database (HSPAMM). Hawaii Med J. 2002 Dec; 61(12):275-9.
Score: 0.049
-
Marques de Menezes EG, Deng X, Liu J, Bowler SA, Shikuma CM, Stone M, Hunt PW, Ndhlovu LC, Norris PJ. Plasma CD16+ Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV+ Adults on Combination Antiretroviral Therapy. mBio. 2022 06 28; 13(3):e0300521.
Score: 0.047
-
Premeaux TA, D'Antoni ML, Abdel-Mohsen M, Pillai SK, Kallianpur KJ, Nakamoto BK, Agsalda-Garcia M, Shiramizu B, Shikuma CM, Gissl?n M, Price RW, Valcour V, Ndhlovu LC. Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. J Neurovirol. 2019 04; 25(2):150-161.
Score: 0.037
-
D'Antoni ML, Mitchell BI, McCurdy S, Byron MM, Ogata-Arakaki D, Chow D, Mehta NN, Boisvert WA, Lefebvre E, Shikuma CM, Ndhlovu LC, Baumer Y. Cenicriviroc inhibits trans-endothelial passage of monocytes and is associated with impaired E-selectin expression. J Leukoc Biol. 2018 12; 104(6):1241-1252.
Score: 0.037
-
O-charoen P, Ndhlovu LC, Gangcuangco LM, Keating SM, Norris PJ, Ng RC, Mitchell BI, Shikuma CM, Chow DC. Albuminuria is associated with elevated acute phase reactants and proinflammatory markers in HIV-infected patients receiving suppressive combination antiretroviral therapy. AIDS Res Hum Retroviruses. 2014 Dec; 30(12):1185-91.
Score: 0.028
-
Sullivan K, Shikuma CM, Chow D, Cornelius E, Romine RK, Lindsey RA, Stickley CD, Kimura IF, Hetzler RK. Aerobic fitness levels and validation of a non exercise VO2max prediction equation for HIV-infected patients on HAART. HIV Clin Trials. 2014 Mar-Apr; 15(2):69-77.
Score: 0.027
-
Tongma C, Shikuma CM, Nakamoto BK, Kallianpur KJ, Umaki TM, Barbour JD, Ndhlovu L, Parikh NI, Chow DC. Albuminuria as a marker of cardiovascular risk in HIV-infected individuals receiving stable antiretroviral therapy. Hawaii J Med Public Health. 2013 Sep; 72(9 Suppl 4):34-8.
Score: 0.026
-
McLinden RJ, Paris RM, Polonis VR, Close NC, Su Z, Shikuma CM, Margolis DM, Kim JH. Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). AIDS. 2012 Jan 02; 26(1):1-9.
Score: 0.023
-
Pumpradit W, Ananworanich J, Lolak S, Shikuma C, Paul R, Siangphoe U, Chaoniti N, Kaew-On P, Paris R, Ruxrungtham K, Valcour V. Neurocognitive impairment and psychiatric comorbidity in well-controlled human immunodeficiency virus-infected Thais from the 2NN Cohort Study. J Neurovirol. 2010 Feb; 16(1):76-82.
Score: 0.020
-
Hetzler RK, Stickley CD, Shikuma CM, Chow D, Takahashi CE, Kimura IF, Barnett AT. Validation of the human activity profile in HIV-positive individuals on HAART. HIV Clin Trials. 2009 Jul-Aug; 10(4):254-60.
Score: 0.019
-
Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23.
Score: 0.017
-
Shiramizu B, Ratto-Kim S, Sithinamsuwan P, Nidhinandana S, Thitivichianlert S, Watt G, deSouza M, Chuenchitra T, Sukwit S, Chitpatima S, Robertson K, Paul R, Shikuma C, Valcour V. HIV DNA and dementia in treatment-na?ve HIV-1-infected individuals in Bangkok, Thailand. Int J Med Sci. 2006 Dec 06; 4(1):13-8.
Score: 0.016
-
Valcour V, Yee P, Williams AE, Shiramizu B, Watters M, Selnes O, Paul R, Shikuma C, Sacktor N. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection--The Hawaii Aging with HIV Cohort. J Neurovirol. 2006 Oct; 12(5):387-91.
Score: 0.016
-
Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, Aguon J, Valcour V. Circulating proviral HIV DNA and HIV-associated dementia. AIDS. 2005 Jan 03; 19(1):45-52.
Score: 0.014
-
Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS. 2002 Sep 27; 16(14):1915-23.
Score: 0.012